WHAT IS CLAIMED IS:

1. A composition for use as a medicament, wherein said composition comprises a nucleic acid that encodes a molecule that has at least 80% sequence identity to amino acids 2132-2319 of mAKAP or a fragment thereof, or has at least 80% sequence identity to SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:14 or a fragment thereof, wherein the molecule inhibits the anchoring of PP2A to mAKAP and inhibits the dephosphorylation activity of protein (serine-threonine) phosphatase 2A (PP2A), resulting in a maintained level of phosphorylation on serum response factor (SRF).

2. Use of the composition of any one of Claims 1 and 3-10 in the manufacture of a medicament for the treatment or prevention of heart failure with reduced ejection fraction in a patient, wherein the medicament is to be administered to the cardiac cells of the patient.

3. The composition of Claim 1, wherein the molecule is amino acids 2132-2319 of mAKAP or a fragment thereof.

4. The composition of Claim 1 or 3, wherein the nucleic acid is in a vector.

5. The composition of Claim 4, wherein the vector is adeno-associated virus (AAV).

6. The composition of Claim 1, wherein the molecule has at least 90% sequence identity to SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:14 or a fragment thereof.

7. The composition of Claim 6, wherein the molecule is SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:14 or a fragment thereof.

8. The composition of Claim 7, wherein the molecule is SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:14.

9. The composition of Claim 1, wherein the molecule has at least 90% sequence identity to amino acids 2132-2319 of mAKAP or a fragment thereof.

10. The composition of Claim 9, wherein the molecule is amino acids 2132-2319 of mAKAP or a fragment thereof.